Anfarm Hellas S.A. - Main Component
Active Substance | Strength | Form |
---|---|---|
BrivaracetamUnder Development | 10mg/ml | Sol.Inf |
BrivaracetamUnder Development | 10mg/ml | Oral Solution |
Budesonide | 0.025% (Tubx30g, x50g, x100g) | Cr.Ext.Us |
Budesonide | 100mcg/Dose (FLx10ml (200 Doses)) | Naspr.Sus |
Butamirate Citrate | 7.5mg/5ml (200ml Bottle) | Syr |
Active Substance | Strength | Form |
---|---|---|
BrivaracetamUnder Development | 10mg/ml | Sol.Inf |
BrivaracetamUnder Development | 10mg/ml | Oral Solution |
Budesonide | 0.025% (Tubx30g, x50g, x100g) | Cr.Ext.Us |
Budesonide | 100mcg/Dose (FLx10ml (200 Doses)) | Naspr.Sus |
Butamirate Citrate | 7.5mg/5ml (200ml Bottle) | Syr |
Active Substance | Strength | Form | Market Availability |
---|---|---|---|
BrivaracetamUnder Development | 10mg/ml | Sol.Inf | Q1 2023 |
BrivaracetamUnder Development | 10mg/ml | Oral Solution | Q2 2023 |
Budesonide | 0.025% (Tubx30g, x50g, x100g) | Cr.Ext.Us | Selected Markets |
Budesonide | 100mcg/Dose (FLx10ml (200 Doses)) | Naspr.Sus | Selected Markets |
Butamirate Citrate | 7.5mg/5ml (200ml Bottle) | Syr | International |